Advanced search
1 file | 840.55 KB

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

(2010) LANCET. 375(9722). p.1267-1277
Author
Organization
Abstract
Background Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook two comprehensive systematic reviews and meta-analyses to establish the effects of adding adjuvant chemotherapy to surgery, or to surgery plus radiotherapy. Methods We included randomised trials, not confounded by additional therapeutic differences between the two groups and that started randomisation on or after Jan 1,1965, which compared surgery plus adjuvant chemotherapy versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery plus adjuvant radiotherapy. Updated individual patient data were collected, checked, and included in meta-analyses stratified by trial. The primary endpoint was overall survival, defined as time from randomisation until death by any cause. All analyses were by intention to treat. Findings The first meta-analysis of surgery plus chemotherapy versus surgery alone was based on 34 trial comparisons and 8447 patients (3323 deaths). We recorded a benefit of adding chemotherapy after surgery (hazard ratio [HR] 0.86, 95% CI 0.81-0.92, p<0.0001), with an absolute increase in survival of 4% (95% CI 3-6) at 5 years (from 60% to 64%). The second meta-analysis of surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy was based on 13 trial comparisons and 2660 patients (1909 deaths). We recorded a benefit of adding chemotherapy to surgery plus radiotherapy (HR 0-88,95% CIl 0.81-0.97, p=0.009), representing an absolute improvement in survival of 4% (95% CI 1-8) at 5 years (from 29% to 33%). In both meta-analyses we noted little variation in effect according to the type of chemotherapy, other trial characteristics, or patient subgroup. Interpretation The addition of adjuvant chemotherapy after surgery for patients with operable non-small-cell lung cancer improves survival, irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery plus radiotherapy.
Keywords
JAPAN STUDY-GROUP, VINORELBINE PLUS CISPLATIN, URACIL-TEGAFUR, SURGERY, THERAPY, UFT, VINDESINE, SURVIVAL, RANDOMIZED CONTROLLED-TRIALS, RESECTED STAGE-I

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 840.55 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Auperin, A, T Le Chevalier, C Le Pechoux, JP Pignon, H Tribodet, S Burdett, LA Stewart, et al. 2010. “Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, in Operable Non-small-cell Lung Cancer: Two Meta-analyses of Individual Patient Data.” Lancet 375 (9722): 1267–1277.
APA
Auperin, A., Le Chevalier, T., Le Pechoux, C., Pignon, J., Tribodet, H., Burdett, S., Stewart, L., et al. (2010). Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. LANCET, 375(9722), 1267–1277.
Vancouver
1.
Auperin A, Le Chevalier T, Le Pechoux C, Pignon J, Tribodet H, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. LANCET. 2010;375(9722):1267–77.
MLA
Auperin, A, T Le Chevalier, C Le Pechoux, et al. “Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, in Operable Non-small-cell Lung Cancer: Two Meta-analyses of Individual Patient Data.” LANCET 375.9722 (2010): 1267–1277. Print.
@article{1186664,
  abstract     = {Background Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook two comprehensive systematic reviews and meta-analyses to establish the effects of adding adjuvant chemotherapy to surgery, or to surgery plus radiotherapy.
Methods We included randomised trials, not confounded by additional therapeutic differences between the two groups and that started randomisation on or after Jan 1,1965, which compared surgery plus adjuvant chemotherapy versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery plus adjuvant radiotherapy. Updated individual patient data were collected, checked, and included in meta-analyses stratified by trial. The primary endpoint was overall survival, defined as time from randomisation until death by any cause. All analyses were by intention to treat.
Findings The first meta-analysis of surgery plus chemotherapy versus surgery alone was based on 34 trial comparisons and 8447 patients (3323 deaths). We recorded a benefit of adding chemotherapy after surgery (hazard ratio [HR] 0.86, 95\% CI 0.81-0.92, p{\textlangle}0.0001), with an absolute increase in survival of 4\% (95\% CI 3-6) at 5 years (from 60\% to 64\%). The second meta-analysis of surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy was based on 13 trial comparisons and 2660 patients (1909 deaths). We recorded a benefit of adding chemotherapy to surgery plus radiotherapy (HR 0-88,95\% CIl 0.81-0.97, p=0.009), representing an absolute improvement in survival of 4\% (95\% CI 1-8) at 5 years (from 29\% to 33\%). In both meta-analyses we noted little variation in effect according to the type of chemotherapy, other trial characteristics, or patient subgroup.
Interpretation The addition of adjuvant chemotherapy after surgery for patients with operable non-small-cell lung cancer improves survival, irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery plus radiotherapy.},
  author       = {Auperin, A and Le Chevalier, T and Le Pechoux, C and Pignon, JP and Tribodet, H and Burdett, S and Stewart, LA and Tierney, JF and Stephens, RJ and Arriagada, R and Higgins, JP and Johnson, DH and van Meerbeeck, J and Parmar, MKB and Souhami, RL and Bergman, B and Dautzenberg, B and Douillard, JY and Dunant, A and Endo, C and Girling, DJ and Imaizumi, M and Kato, H and Keller, SM and Kimura, H and Knuuttila, A and Kodama, K and Komaki, R and Kris, MG and Lad, T and Mineo, T and Park, JH and Piantadosi, S and Pyrhonen, S and Rosell, R and Scagliotti, GV and Seymour, LW and Shepherd, FA and Spiro, SG and Strauss, GM and Sylvester, R and Tada, H and Tanaka, F and Torri, V and Wada, H and Waller, D and Xu, GC},
  issn         = {0140-6736},
  journal      = {LANCET},
  keyword      = {JAPAN STUDY-GROUP,VINORELBINE PLUS CISPLATIN,URACIL-TEGAFUR,SURGERY,THERAPY,UFT,VINDESINE,SURVIVAL,RANDOMIZED CONTROLLED-TRIALS,RESECTED STAGE-I},
  language     = {eng},
  number       = {9722},
  pages        = {1267--1277},
  title        = {Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data},
  url          = {http://dx.doi.org/10.1016/S0140-6736(10)60059-1},
  volume       = {375},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: